UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
|
||||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 | Results of Operations and Financial Condition. |
On August 8, 2022, IN8bio, Inc. (the “Company”) filed a registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) in connection with a proposed offering. In connection with such offering, the Company provided an preliminary estimate that its net loss for the three and six months ended June 30, 2022 is expected to be approximately $7.2 million and $13.3 million, respectively. In addition, the Company estimated that its cash as of June 30, 2022 was approximately $25.7 million and that it had 18,838,471 shares of common stock outstanding as of June 30, 2022. These preliminary estimates are not a comprehensive statement of the Company’s financial results for the three and six months ended June 30, 2022 and have not been audited, reviewed or compiled by its independent registered public accounting firm. The Company’s actual cash balance and shares of common stock outstanding as of June 30, 2022 may differ from these estimates due to the completion of the Company’s quarter-end closing and review procedures.
The information provided in this Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IN8bio, Inc. | ||||||
Date: August 8, 2022 | By: | /s/ Patrick McCall | ||||
Patrick McCall | ||||||
Chief Financial Officer and Secretary (Principal Financial and Accounting Officer) |
Document and Entity Information |
Aug. 08, 2022 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001740279 |
Document Type | 8-K |
Document Period End Date | Aug. 08, 2022 |
Entity Registrant Name | IN8bio, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-39692 |
Entity Tax Identification Number | 82-5462585 |
Entity Address, Address Line One | 350 5th Avenue |
Entity Address, Address Line Two | Suite 5330 |
Entity Address, City or Town | New York |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 10118 |
City Area Code | 646 |
Local Phone Number | 600-6438 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.0001 par value |
Trading Symbol | INAB |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
[4\QZ&^9/7XR],\DF(H=,Y";)B&
M\5.$N[H1@5DWXI@- 1/AAST?"E:J/V$4K^R%UD
MG1K*7C0]K1>@OI]EB1]GB)9HMUS=*:P,(5X8B6$T'K&,GWPI>6A776Z'6BTG
M=ZHG(T7-PW'#=3J6)__<[1E5E]">4(O'G?J(G6(WJWA&Q13.N=U:;EM=6.5Z
M+3/7ZB W*:@ISKU/2BZS&:[O4JFI397<'=3\R34<)%
MSHMB+!$'6XMG(T[B"NEB^\Y%U^I6,SY5O=T_:"=S]> 9=@Y:+=E\W\^\^''P
MF6<7&ROK ]JYE[8\>;/G"[FD^25>Z%Q!-WS_4CTKB/V:F$JG*]Y-ZX>#>;M"
M[9KDW